TASE

Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma

Retrieved on: 
Thursday, December 14, 2023

Yanay Ofran, Ph.D., CEO and founder of Biolojic Design: "We are excited about the opportunity to work with Teva and bring hope to patients.

Key Points: 
  • Yanay Ofran, Ph.D., CEO and founder of Biolojic Design: "We are excited about the opportunity to work with Teva and bring hope to patients.
  • The potential therapy we designed for Atopic Dermatitis and Asthma is another example of how AI can revolutionize drug development.
  • Under the terms of the agreement, Teva will receive exclusive rights to develop, manufacture and commercialize BD9 worldwide.
  • Biolojic is also eligible to receive tiered royalties in the mid-single to low-double digit on product sales should Teva successfully commercialize a therapy.

Perion Acquires Hivestack, a Leading Global Full-Stack Digital Out-Of-Home (DOOH) Platform

Retrieved on: 
Tuesday, December 12, 2023

DOOH advertising transforms ordinary public spaces into dynamic experiences, engaging audiences with eye-catching, personalized content in real-time.

Key Points: 
  • DOOH advertising transforms ordinary public spaces into dynamic experiences, engaging audiences with eye-catching, personalized content in real-time.
  • It harnesses cutting-edge technologies to target, deliver and measure unforgettable, immersive ads that connect brands with people on the go.
  • With the acquisition of Hivestack, a programmatic DOOH technology innovator since 2017, Perion is entering an exciting market at its nascent stage, positioning the company to capitalize on its anticipated growth.
  • This global footprint will enable Perion to capitalize on economic trends impacting advertising budgets globally, and offer a variety of solutions in these additional markets.

New Data from Glassbox Reveals Consumer Expectations Versus Reality for Digital Holiday Shopping Experiences

Retrieved on: 
Monday, December 11, 2023

Glassbox (TASE: GLBX), a leading provider of digital experience intelligence for web and mobile applications, today announced the results of a new consumer shopping survey, “Digital Holiday Shopping Experiences: Expectations vs. Reality.” The results showcase how the consumer shopping experience is evolving for digital and mobile channels with increasingly high customer expectations placed on ease of navigation, convenience and personalized shopping experiences.

Key Points: 
  • Glassbox (TASE: GLBX), a leading provider of digital experience intelligence for web and mobile applications, today announced the results of a new consumer shopping survey, “Digital Holiday Shopping Experiences: Expectations vs. Reality.” The results showcase how the consumer shopping experience is evolving for digital and mobile channels with increasingly high customer expectations placed on ease of navigation, convenience and personalized shopping experiences.
  • “The data clearly shows that customers continue to shift their holiday shopping to digital channels and have high expectations for their digital customer experience.
  • “Delivering seamless digital experiences is paramount to capturing holiday shopping revenue and also to building long-term customer loyalty.
  • To read more about the results for part one of the survey, visit: Cyber Weekend shopping plans: Survey says digital experiences matter.

New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity

Retrieved on: 
Wednesday, December 6, 2023

Migraine and obesity are both associated with high levels of disability3 and both conditions are more prevalent amongst females5,6.

Key Points: 
  • Migraine and obesity are both associated with high levels of disability3 and both conditions are more prevalent amongst females5,6.
  • The post hoc analysis of the HALO-LTS1 and FOCUS2 phase 3 studies compared the safety and efficacy of fremanezumab migraine preventive treatment in obese migraine patients vs normal weight migraine patients for a period of 6 months.
  • The analysis showed that the efficacy of fremanezumab was the same in migraine patients with BMI-high vs BMI-normal:
    At baseline, monthly migraine days in migraine patients with BMI-high vs BMI-normal were 13.7 vs 13.6 respectively.
  • After 6 months of treatment with fremanezumab, monthly migraine days in migraine patients with BMI-high vs BMI-normal was reduced to 6.8 vs 7.2 respectively.

Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Retrieved on: 
Monday, December 4, 2023

Can-Fite completed the protocol design of the CF102-222PC clinical study entitled: “A Phase II Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma”.

Key Points: 
  • Can-Fite completed the protocol design of the CF102-222PC clinical study entitled: “A Phase II Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma”.
  • This is a multicenter open-label trial in patients with advanced pancreatic adenocarcinoma whose disease has progressed on at least 1st-line therapy or who refuse standard treatment.
  • The trial will evaluate the safety, clinical activity, and pharmacokinetics (PK) of Namodenoson in this population.
  • “This Phase IIa study is designed as an open-label one, enabling us to assess the safety and potential efficacy of Namodenoson in pancreatic cancer patients whose disease has progressed despite first-line treatment.

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Retrieved on: 
Thursday, November 30, 2023

(NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results for the nine months ended September 30, 2023.

Key Points: 
  • (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results for the nine months ended September 30, 2023.
  • Financial income, net for the nine months ended September 30, 2023 was $0.38 million compared to financial expense, net of $0.14 million for the same period in 2022.
  • The decrease in financial expense, net was mainly due to revaluation of our short-term investment and increase in interest income from deposits in 2023.
  • The Company's consolidated financial results for the nine months ended September 30, 2023 are presented in accordance with US GAAP Reporting Standards.

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

Retrieved on: 
Thursday, November 30, 2023

Inflammatory bowel disease (IBD) is the term for two conditions -- Crohn’s disease and ulcerative colitis – characterized by chronic inflammation of the gastrointestinal (GI) tract. Prolonged inflammation results in damage to the GI tract. The common symptoms for both conditions are persistent diarrhea, rectal bleeding, abdominal pain, fatigue, and weight loss. An estimated ~10 million people worldwide live with IBD.

Key Points: 
  • Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY).
  • TEV '574 is currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease.
  • As announced on October 4th, 2023, under the terms of the agreement, Teva will receive an upfront payment of $500 million shortly after closing and up to $1 billion in development and launch milestones.
  • Inflammatory bowel disease (IBD) is the term for two conditions -- Crohn’s disease and ulcerative colitis – characterized by chronic inflammation of the gastrointestinal (GI) tract.

Perion Network Announces Conference Participation in December 2023

Retrieved on: 
Tuesday, November 28, 2023

Perion Network Ltd. (NASDAQ and TASE: PERI) a global technology company whose synergistic solutions serve all major digital advertising channels - including search, social, display, and video/CTV, announces today that it will participate in the following conferences:

Key Points: 
  • Perion Network Ltd. (NASDAQ and TASE: PERI) a global technology company whose synergistic solutions serve all major digital advertising channels - including search, social, display, and video/CTV, announces today that it will participate in the following conferences:
    At each of these events, management will host one-on-one meetings with investors.
  • To schedule a meeting with the Company, please contact your representative at UBS and Raymond James.
  • The company will also participate in a fireside chat on December 5 at 9:10am Eastern Time.
  • A live webcast will be available on the company’s website and can be accessed by the following link:

Perion Appoints CEO Tal Jacobson to its Board of Directors

Retrieved on: 
Wednesday, November 22, 2023

Perion Network Ltd. (NASDAQ and TASE: PERI), a global technology company whose synergistic solutions serve all major digital advertising channels, including search, social, display, and video/CTV, announced today the appointment of Tal Jacobson, the Company's CEO, to the Board of Directors.

Key Points: 
  • Perion Network Ltd. (NASDAQ and TASE: PERI), a global technology company whose synergistic solutions serve all major digital advertising channels, including search, social, display, and video/CTV, announced today the appointment of Tal Jacobson, the Company's CEO, to the Board of Directors.
  • Tal is replacing former CEO, Doron Gerstel, following a transition and onboarding period.
  • “I am happy to welcome Tal as a member of the Board,” said Eyal Kaplan, Perion’s Chairman of the Board.
  • I look forward to continuing to work with the Board and the company’s management in positioning Perion for future success.”

Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

Retrieved on: 
Tuesday, November 21, 2023

A patient with advanced HCC that was enrolled in the former Can-Fite Phase II study continues to receive treatment with namodenoson and has now an overall survival of 6.9 years with the disappearance of ascites, normal liver function, and good quality of life and defined as a complete response.

Key Points: 
  • A patient with advanced HCC that was enrolled in the former Can-Fite Phase II study continues to receive treatment with namodenoson and has now an overall survival of 6.9 years with the disappearance of ascites, normal liver function, and good quality of life and defined as a complete response.
  • Namodenoson has Orphan Drug status with both the FDA and EMA, as well as Fast Track Status with the FDA for the treatment of HCC.
  • An interim analysis will be conducted by an Independent Data Monitoring Committee (IDMC) after 50% of enrolled patients are treated.
  • According to the American Cancer Society, liver cancer accounts for more than 700,000 deaths globally each year.